What if aging could be reversed? That question is now being tested in a human patient for the first time. The treatment, called ER-100, was developed by Life Biosciences, a biotechnology company based in Boston. Its first recipient was a patient experiencing vision loss from a progressive eye disease, who received a single injection directly into the eye.
The target is the optic nerve. But the ambition behind the therapy reaches much further. ER-100 is built on a theory that challenges one of biology’s most fundamental assumptions: that aging is a one-way process. Instead, researchers believe it may be possible to restore cells to a more youthful state, reversing some of the damage that accumulates over time.
If the approach works, its impact could extend far beyond vision loss, opening the door to treatments that address aging itself rather than just its symptoms.
Why the Eye Became Ground Zero for a Reverse Aging Drug
Glaucoma is a common age-related eye disease that can cause permanent vision loss, with an estimated 4.22 million Americans living with it. Nearly half of those affected are unaware of their condition. Globally, the numbers are staggering. An estimated 80.5 million people worldwide are affected by open-angle glaucoma in 2024 alone.
Optic neuropathies are a group of disorders characterized by damage to retinal ganglion cells – the primary neurons connecting the eye to the brain. ER-100 works by using controlled expression of three transcription factors – OCT4, SOX2, and KLF4 – to restore cellular function by resetting the epigenetic code to more youthful patterns of gene expression. In plain terms: it tries to convince aging, damaged cells to behave the way they did when they were young.
The reason Life Biosciences started with the eye isn’t accidental. The eye functions as a controlled test model to validate biosafety before considering systemic applications. Vision loss is measurable. The eye is accessible. And if something goes wrong, the damage is contained.
What Epigenetic Reprogramming Actually Means
Every cell in your body carries the same DNA. What makes a retinal cell different from a liver cell isn’t the sequence of genes but which genes are switched on or off. Those switches – chemical marks sitting on top of the DNA – are called epigenetic controls. They change over a lifetime, and those changes are a core driver of how and why we age.
These marks, known as epigenetic changes, may contribute to cellular decline. ER-100 is designed to address cellular aging through epigenetic reprogramming, working by delivering genetic instructions for producing three proteins, collectively referred to as OSK, that may help reverse these changes and restore cells to a more youthful state.
These factors don’t modify the DNA itself, but reorganize epigenetic marks including DNA methylation, chromatin remodeling, and histone modifications, restoring more youthful gene expression patterns. The critical distinction: ER-100 isn’t rewriting your genetic code. The therapy does not alter the participant’s existing genes.
The science of epigenetic aging has been building for decades, but turning it into an approved human therapy required one more piece: a controllable on/off switch.
The Antibiotic That Controls the Whole System
The therapy deployed in this trial uses a modified adeno-associated virus (AAV) vector to deliver OSK to retinal cells, and the AAV has been engineered to remove its ability to cause infectious disease. Getting the genes in is only half the challenge. The other half is making sure they only activate when you want them to.
The solution is as simple as it is elegant. Systemic doxycycline is administered for 8 weeks – 56 days – to activate OSK expression. Doxycycline is a common, widely-used antibiotic. When patients take it daily, the reprogramming therapy switches on. When they stop, it switches off. This on/off mechanism gives clinicians a direct kill switch if any safety signals emerge during the trial – stopping the antibiotic stops the reprogramming.
ER-100 has demonstrated safety and efficacy in multiple preclinical animal models by local injection into the eye, delivered intravitreally. In non-human primates with an injury mimicking NAION – non-arteritic anterior ischemic optic neuropathy, essentially a stroke of the eye – ER-100 significantly mitigated deficits in pattern electroretinogram responses and axon density in both prevention and rescue treatment models, suggesting it effectively targets retinal ganglion cells and reduces visual function loss.
The Yamanaka Factors and the Cancer Problem
The three proteins at the heart of ER-100 – OCT4, SOX2, and KLF4 – belong to a family made famous in 2006, when Japanese scientist Shinya Yamanaka showed that four such factors could reprogram adult cells back into stem cells. Yamanaka was awarded the 2012 Nobel Prize along with Sir John Gurdon “for the discovery that mature cells can be reprogrammed to become pluripotent.” That discovery also raised an immediate alarm: the fourth factor in the original set, c-MYC, is closely tied to cancer.
Life Bio’s approach allows for the controlled expression of three of the four Yamanaka factors – OCT-4, SOX-2, and KLF-4 (OSK) – and ER-100 is the first ever cellular rejuvenation therapy using epigenetic reprogramming to receive FDA clearance to enter human clinical trials. Dropping c-MYC from the formula is a deliberate risk-reduction strategy. By excluding c-MYC, a factor associated with uncontrolled growth, the strategy is intended to lower tumor risk.
This partial reprogramming approach – using just three factors rather than all four – is the key conceptual advance. Full reprogramming would erase a cell’s identity entirely, turning it into something that no longer knows it’s supposed to be a retinal cell. Partial reprogramming aims to reset the epigenetic clock without erasing the cell’s function.
The scientific roots of this approach trace back to a significant 2020 experiment. Researchers at Harvard Medical School showed that expression of OCT4, SOX2, and KLF4 in mouse retinal ganglion cells restored youthful DNA methylation patterns and transcriptomes, promoted axon regeneration after injury, and reversed vision loss in a mouse model of glaucoma and in aged mice.
What the Trial Actually Looks Like
The IND clearance, announced January 28, 2026, marks the first ever cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trials. Then, on June 9, 2026, Life Biosciences confirmed this clinical study represents the first opportunity to test whether restoring that cellular information can ameliorate human disease.
The trial design reflects the usual caution of first-in-human research, layered with a few features specific to how unusual this therapy is. The Phase 1 study will enroll individuals with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy to assess safety, tolerability, immune responses, and impact on multiple visual assessments.
The trial is designed to evaluate the safety and tolerability of ER-100, an investigational epigenetic therapy candidate intended for age-related optic neuropathies. Up to 18 participants are planned for enrollment: 12 with open-angle glaucoma and 6 with NAION. Participants with open-angle glaucoma are enrolled first in a dose escalation phase before NAION patients enter the study – a sequential structure designed to manage risk carefully, adjusting doses based on how earlier participants respond.
A total of 15 clinic visits is planned for the study: 10 in the first 6 months, then one visit per year through Year 5. That five-year follow-up window is substantial for a Phase 1 trial and reflects the unknowns involved in a therapy that asks cells to change their fundamental biological behavior.
Read More: 6 Daily Practices That Contribute to Healthy, Radiant Aging
The Conditions Being Targeted
The two diseases in scope are ones with no existing treatment capable of reversing the damage they cause. NAION is the most common acute optic neuropathy in adults over fifty. It occurs when blood supply to the optic nerve is suddenly interrupted – a stroke, effectively, but in the eye. Vision loss typically happens overnight and is permanent.
Glaucoma works more slowly. It’s a neurodegenerative disease of the retina characterized by the irreversible loss of retinal ganglion cells. These cells are the sole projection neurons that connect the eye with the brain. Once they’re gone under current medical standards, they don’t come back. Current treatments for glaucoma manage intraocular pressure to slow progression – they do nothing to restore cells that have already died.
That’s the gap ER-100 is trying to fill. Not slowing the decline, but reversing it.
The Risks the Scientists Are Watching
The scientific community has greeted this milestone with a mix of genuine excitement and real caution. Professor Pete Williams at the Centre for Eye Research Australia heads the Neuroprotection and Repair Unit and investigates what causes cells in the eye to die in glaucoma, discovering ways to help them survive – making him precisely the kind of independent expert watching this trial. His concern, reported by science media covering the study’s launch, is that a failure at this stage – a serious adverse event tied to reprogramming gone wrong – could set the entire field back significantly.
The risks aren’t abstract. Partial reprogramming has never been tested in a living human before. The three OSK factors do not include c-MYC, which reduces cancer risk, but researchers will still be monitoring carefully for any signs of uncontrolled cellular behavior. The five-year follow-up exists precisely because some potential effects – both beneficial and harmful – may take time to manifest.
Most current longevity interventions address the consequences of aging. ER-100 is conceptually different: it does not modulate the damage, it attempts to restore the original cellular programming. That upstream ambition is what makes it remarkable – and what makes the safety data from this small trial so consequential for the field.
What to Do With This Information Now
The honest answer is that this trial won’t change anything you can do tomorrow morning. With 18 participants and a primary focus on safety – not efficacy – the results are years away from informing any treatment decisions for patients. If the trial confirms that ER-100 is safe, larger trials will follow. If those show that it restores visual function, it would be the first therapy of its kind: one that doesn’t just slow the loss of neurons but gives them back their youthful biology.
Beyond ER-100, Life Biosciences is a clinical-stage biotechnology company whose proprietary Partial Epigenetic Reprogramming platform utilizes OCT4, SOX2, and KLF4 to restore older and damaged cells to a younger and healthier state, with applications being developed for multiple organs. If safety and functional efficacy are demonstrated in the eye, the implications could extend to diseases such as Parkinson’s or Alzheimer’s, where epigenetic dysfunction contributes to neuronal loss.
For anyone currently living with glaucoma or at risk of NAION, the most practical step is discussing your optic nerve health with an ophthalmologist now. The treatments that exist today – pressure-lowering eye drops, laser therapy, surgery – can slow glaucoma’s progression significantly when started early. That remains the evidence-based standard of care while longer-term research matures.
The June 9 injection didn’t cure aging. It asked, for the first time in a living human being, whether aging could be asked to go in reverse. The answer to that question is still coming.
Disclaimer: The author is not a licensed medical professional. The information provided is for general informational and educational purposes only and is based on research from publicly available, reputable sources. It is not intended to constitute, and should not be relied upon as, medical advice, diagnosis, or treatment. Always consult a licensed physician or other qualified healthcare provider regarding any medical condition, symptoms, or medications. Do not disregard, avoid, or delay seeking professional medical advice or treatment because of information contained herein.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: 8 Anti-Aging Fruits to Help Live a Long and Healthy Life